Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial - Concepedia

Concepedia

Publication | Closed Access

Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial

110

Citations

17

References

2023

Year

Andrew McGarry, Shane Rosanbalm, Mika Leinonen, C. Warren Olanow, Dennis To, Adam Bell, Daniel J. Lee, Jamie Chang, Jordan Dubow, Rohit Dhall,

The Lancet Neurology

Untreated ParkinsonNeurodegenerative DiseasesParkinson DiseaseClinical NeurologyPlacebo-controlled TrialClinical NeuroscienceNeurologyMedicine

References

	Year	Citations

Page 1

Page 1